



**HAL**  
open science

## Executive functioning and risk-taking behavior in Parkinson's disease patients with impulse control disorders

Fanny Pineau, Emmanuel Roze, Lucette Lacomblez, Anne-Marie Bonnet, Marie Vidailhet, Virginie Czernecki, Jean-Christophe Corvol

► **To cite this version:**

Fanny Pineau, Emmanuel Roze, Lucette Lacomblez, Anne-Marie Bonnet, Marie Vidailhet, et al.. Executive functioning and risk-taking behavior in Parkinson's disease patients with impulse control disorders. *Journal of Neural Transmission*, 2016, 123 (6), pp.573-581. 10.1007/s00702-016-1549-y . hal-01311564

**HAL Id: hal-01311564**

**<https://hal.sorbonne-universite.fr/hal-01311564>**

Submitted on 4 May 2016

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **Executive functioning and risk-taking behavior in Parkinson's disease patients**  
2 **with impulse control disorders**

3  
4 **Fanny Pineau<sup>a,d\*</sup> MA, Emmanuel Roze<sup>a</sup> MD, PhD, Lucette Lacomblez<sup>b</sup> MD, PhD, Anne-Marie**  
5 **Bonnet<sup>a</sup> MD, Marie Vidailhet<sup>a</sup> MD, PhD, Virginie Czernecki<sup>c</sup> PhD, Jean-Christophe Corvol<sup>a</sup>**  
6 **MD, PhD.**

7  
8 <sup>a</sup> Sorbonne Universités, UPMC Univ Paris 06, and INSERM UMRS\_1127 and CIC\_1422, and  
9 CNRS UMR\_7225, and AP-HP, and ICM, Hôpital Pitié-Salpêtrière, Département des maladies du  
10 système nerveux, F-75013, Paris, France

11 <sup>b</sup> Sorbonne Universités, UPMC Univ Paris 06, and INSERM UMRS\_1146 and CIC\_1422, and AP-  
12 HP, and ICM, Hôpital Pitié-Salpêtrière, Département des maladies du système nerveux, F-75013,  
13 Paris, France

14 <sup>c</sup> Sorbonne Universités, UPMC Univ Paris 06, INSERM UMRS\_975, and AP-HP, and ICM,  
15 Hôpital Pitié-Salpêtrière, Département des maladies du système nerveux, F-75013, Paris, France

16 <sup>d</sup> Service de Neurologie, Hôpitaux Civils de Colmar, 39 avenue de la liberté, F-68000, Colmar,  
17 France

18  
19 **\*Corresponding author:**

20 Fanny PINEAU

21 fanny.pineau@ch-colmar.fr

22 Hôpitaux Civils de Colmar

23 Service de Neurologie

24 Bâtiment 59

25 39 avenue de la Liberté

26 68000 COLMAR

27 +33672055058

28  
29  
30 **Keywords:** Parkinson's disease; Impulse control disorders; Executive functions; Risk-taking  
31 behavior; Metacognitive skills

32  
33 **Acknowledgments:** *The authors thank the patients who participated to the study.*

34 **COMPLIANCE WITH ETHICAL STANDARDS**

35

36

37 **Funding source of the study:** none

38

39 **Financial Disclosures/Conflict of Interest:** FP has received grants from Novartis Pharma. EFR has  
40 received grants from “poste d'accueil” APHP/CNRS, grants from INSERM (COSSEC), grants from  
41 APHP (DRC-PHRC), grants from Fondation pour la Recherche sur le Cerveau (FRC), grants,  
42 personal fees and non-financial support from Merz-pharma, grants and personal fees from Orkyn,  
43 grants from IP Santé, grants and personal fees from Ultragenyx, personal fees from Novartis,  
44 personal fees and non-financial support from Ipsen Pharma, non financial supports from Teva, non-  
45 financial support from Abbvie, non-financial support from Dystonia Europe, non-financial support  
46 from the Georgian Medical and Public Health Association, non financial support from the  
47 International Federation of Clinical neurophysiology, non-financial support from the Movement  
48 Disorders Society. LL has received personal fees from Novartis Pharma, personal fees from GE,  
49 non-financial supports from Merck-Serono, grants from Sanofi-Aventis, grants from GSK, grants  
50 from Cytokinetic. MV has received personal fees from Mertz, non-financial support from  
51 Movement Disorders Society, non-financial support from EAN. JCC has received personal fees and  
52 non-financial support from abbvie, personal fees from Amarentus, personal fees from Zambon,  
53 personal fees from Pfizer, personal fees from Clevexel, non-financial support from UCB, grants  
54 from Sanofi-Aventis, grants from Ipsen, grants from the Michael J. Fox foundation, and own stock  
55 in B&A Therapeutics.

56

57

58

59 **ABSTRACT**

60 Background: Impulse control disorders (ICD) are common in Parkinson's disease (PD) and are  
61 associated with dopaminergic medication. The purpose of this study was to investigate executive  
62 function and risk-taking behavior in PD patients with ICD.

63 Methods: 17 PD patients with ICD (ICD-PD) were compared to 20 PD patients without ICD  
64 (CTRL-PD) using neuropsychological and experimental tasks. Executive functions were assessed  
65 using standard executive testing (Conner's Performance Test, Modified Wisconsin Card Sorting  
66 Test, Trail Making Test and phonological verbal fluency). Subjects were also submitted to an  
67 experimental gambling task consisted of three decks of money cards: neutral deck (equal  
68 opportunity for gains as losses), winning deck (small amount of money with a positive balance) and  
69 loser deck (high amount of money with a negative balance), evaluating risk-taking behavior  
70 (number of cards picked in each deck) and valuation of the reward (subjective appreciation of the  
71 value of each deck).

72 Results: There was no significant difference in executive functioning between groups. Both groups  
73 selected more cards in the losing deck (high amount of money) as compared to the neutral deck  
74 (Mann-Whitney test, ICD-PD,  $p=0,02$ ; CTRL-PD,  $p=0,003$ ) and to the winning deck (Mann-  
75 Whitney test, ICD-PD  $p=0,0001$ ; CTRL-PD  $p=0,003$ ), suggesting an increased risk-taking behavior.  
76 Interestingly, we found that ICD-PD patients estimated the value of decks differently from CTRL-  
77 PD patients, taking into account mainly the positive reinforced value of the decks (Mann Whitney  
78 test,  $p=0,04$ ).

79 Discussion: This study showed that executive pattern and risk-taking behavior are similar between  
80 ICD-PD and CTRL-PD patients. However, ICD-PD patients showed a specific deficit of the  
81 subjective estimation of the reward. Links between this deficit and metacognitive skills are  
82 discussed.

83

## 84 INTRODUCTION

85

86 Impulse control disorders (ICD) are behavioral disorders characterized by the failure to  
87 resist an impulse, inability to cut down and unsuccessful attempts to control a specific behavior  
88 (Evans et al. 2009). In Parkinson's disease (PD), the lifetime prevalence of ICD is about 14%  
89 (Weintraub et al. 2010). The most frequent ICD in PD are pathological gambling (PG),  
90 hypersexuality (HS), compulsive shopping (CS) and compulsive eating (CE) (Evans et al. 2009;  
91 Weintraub et al. 2010). The high prevalence of ICD in PD has been associated to the dopaminergic  
92 treatment, particularly to dopamine agonists (DA) (Weintraub et al. 2010). A possible hypothesis for  
93 the association between DA treatment and ICD involves their relative selectivity of D2-D3  
94 dopamine-receptor. Those receptors are particularly abundant in the ventral striatum known to play  
95 a role in behavioral addiction and substance use disorders (Gurevich et al. 1999). In addition to DA  
96 exposure, clinical risk factors associated with ICD in PD are male gender, younger age, younger age  
97 at onset of PD and longer disease duration, personal or family history of alcohol or psychiatric  
98 disorders, high novelty seeking personalities, impulsivity and alexithymia traits (Weintraub et al.  
99 2010; Voon et al. 2011a; Goerlich-Dobre et al. 2014). Although the pathological mechanisms  
100 remain largely unknown, the level of dopamine denervation of the fronto-striatal circuitry, involved  
101 in executive as well as decision-making functions, has been associated to ICD in PD (Cilia et al.  
102 2011; Vriend et al. 2014). Especially, Cilia et al. (2011) found decreased prefrontal cortex,  
103 cingulate, insula, parahippocampal gyrus and striatal resting perfusion with increasing gambling  
104 severity in PG patients. These regions are involved in reward and risk processing, error detection,  
105 learning, decision-making and impulse control. Furthermore, the authors showed an anterior  
106 cingulate cortex-striatum disconnection, which could underline a specific impairment in ability to  
107 shift behavior after negative outcomes, leading patients to continue their behavior despite dramatic  
108 consequences.

109 A growing amount of studies attempted to investigate the cognitive characteristics associated  
110 with ICD in PD. Some studies found preserved cognitive functions (Siri et al. 2010; Djamshidian et  
111 al. 2011a; Mack et al. 2013). By contrast, a significant association between executive dysfunction  
112 and ICD has been demonstrated in few studies (Djamshidian et al. 2010; Vitale et al. 2011; Poletti et  
113 al. 2012). Especially, PD patients with PG had more severe impairments in retrieval of verbal and  
114 visuo-spatial information and cognitive flexibility (Santangelo et al. 2009). However, there were  
115 several limitations in these studies including materials used to explore cognitive functioning, often  
116 limited to working memory or global executive assessment.

117 Decision-making, connoting the process of choosing under ambiguous or risky situations the  
118 optimal selection in terms of rewarding or punishing outcomes between several alternative course

119 of actions (Paulus 2005), has been well documented in PD patients (Delazer et al. 2009) and has  
120 been specifically involved in PD patients with ICD (Djamshidian et al. 2010; Rao et al. 2010; Rossi  
121 et al. 2010; Steeves et al. 2009). Especially, Rossi et al. (2010) found that PD patients with PG  
122 obtained poorer performances in a risk-taking under ambiguity task than PD without PG. Using  
123 delay-discounting tasks, several studies showed that altered impulsivity in PD with ICD can  
124 contribute to risk-taking (Voon et al. 2010a; Housden et al. 2010). The pathophysiology underlying  
125 risk-taking behavior in PD with ICD has been explored and involved dysfunction in the reward  
126 system including ventral striatum (Rao et al. 2010; Steeves et al. 2009). For example, using  
127 functional magnetic resonance imaging to quantify resting cerebral blood flow (CBF) and blood  
128 oxygenation level dependent (BOLD), Rao et al. (2010) showed that compared with non-ICD PD  
129 patients, PD patients with ICD demonstrated significantly reduced resting CBF in the right ventral  
130 striatum and significantly diminished BOLD activity in the right striatum during risk-taking. The  
131 influence of pharmacological status on risk taking and impulsivity in PD with ICD has also been  
132 explored (Voon et al. 2010b; Housden et al. 2010; Djamshidian et al. 2011a; Leroi et al. 2013).  
133 These studies broadly concluded that PD patients with ICD tend to make more impulsive and risky  
134 choices while ON dopamine agonist relative to those OFF dopamine agonists or without ICD.

135 Self-awareness, metacognitive skills and their links to ICD have also been recently explored  
136 (Brevers et al. 2013; Mack et al. 2013; Brevers et al. 2014). Self-awareness is usually evaluated by  
137 questionnaire as the Beck Cognitive Insight Scale (BCIS), assessing the understanding of patients'  
138 perspective about their anomalous experiences, their attribution and their aberrant interpretation of  
139 specific life events. Impaired self-awareness or insight has been recognized as a feature of a large  
140 number of neuropsychiatric disorders, including PD (Gilleen et al. 2010). Using the BCIS, Mack et  
141 al. (2013) compared self-awareness of cognitive and behavioral issues in PD patients with and  
142 without ICD and showed that PD patients with ICD are aware of their PD-related problems  
143 including impulsivity. In a different perspective, Brevers et al. (2013; 2014) studied how  
144 metacognitive sensitivity may influence gamblers without PD's decision-making. Metacognition  
145 was assessed by asking participants to wager on their own decision. They found that gamblers tend  
146 to wager high while performing poorly on the Iowa Gambling Task and in a non gambling task,  
147 suggesting that pathological gamblers exhibit impaired metacognition in both gambling like and  
148 more 'neutral' situations of decision-making.

149 The aim of the present study was to investigate executive functions with classical tasks and  
150 risk-taking behavior using a task developed to assess behavioral response and valuation of the  
151 reward in PD patients with ICD (ICD-PD) compared to PD control patients without ICD (CTRL-  
152 PD).

## 154 **PATIENTS AND METHODS**

### 155 **Subjects**

156 Patients were selected from among those attending the movement disorders unit of the Pitié-  
157 Salpêtrière Hospital (Paris, France). All patients met the following inclusion criteria: idiopathic PD  
158 according to the United Kingdom Parkinson's Disease Society Brain Bank and absence of dementia,  
159 according to the MDS task-force criteria (Dubois et al. 2007). All patients obtained score higher  
160 than 130 on the MDRS. Exclusion criteria were a history of ICD prior to PD-onset and treatment by  
161 deep brain stimulation (DBS) before the ICD onset. Between January 2007 and January 2008, all  
162 patients suspected to have ICD in the interview with the neurologist received a specific evaluation  
163 of their ICD by a neuropsychologist. Presence and severity of active ICD were assessed with a  
164 semi-structured interview assessing behavior and mood in PD, the 'Ardouin Scale of Behavior in  
165 Parkinson's Disease' (ASBPD) (Ardouin et al. 2009; Rieu et al. 2015). Inclusion criteria for ICD-  
166 PD patients was a score  $\geq 2$  (moderate to severe) in at least one item in the ASBPD scale of  
167 pathological gambling, compulsive eating, compulsive shopping and hypersexuality. The ASBPD  
168 scale also evaluates compulsive DA and others hyperdopaminergic symptoms such as punding or  
169 any form of hobbyism. Patients who presented punding or form of hobbyism without ICD were not  
170 included in the study. CTRL-PD group was constituted of PD patients, matched with ICD-PD  
171 patients for age, sex, educational level, disease's severity and duration, and who were candidate for  
172 Deep Brain Stimulation (DBS) between the same period, without history of ICD. The CTRL-PD  
173 patients were, therefore, at risks for ICD; their absence was confirmed by a score  $\leq 1$  (none or mild)  
174 in all ICD's items of the ASBPD scale, described below. Informed consent was obtained from all  
175 individual participants included in the study.

176

### 177 **Procedure**

178 The two groups of patients underwent a comprehensive assessment of clinical,  
179 neuropsychiatric and neuropsychological functioning. Assessment was performed in a single  
180 session that lasted approximately 3 hours and when patients were in the 'on' state. Breaks were  
181 introduced to avoid fatigue.

182

### 183 ***Neurological assessment***

184 Patients underwent a neurological examination consisting of the motor section of the  
185 Unified Parkinson's disease Rating Scale (UPDRS, section III) to measure the severity of motor  
186 symptoms in the 'on' state. Most of patients in both groups were at the motor fluctuations stage of  
187 the disease. The demographic data (age, educational level), neurological details (age at PD onset  
188 and PD duration) and treatments (medication type, total L-dopa equivalent daily dose (LEDD) and

189 total L-dopa equivalent daily dose (LEDD) of dopamine agonists) of each patient enrolled were  
190 recorded.

191

## 192 ***Psychological assessment***

193 All patients underwent a psychological assessment consisting of the following:

194 1. the Montgomery and Asberg Depression Scale (MADRS) to evaluate depression, using only  
195 the dysphoria factor defined by Suzuki et al. 2005, naming items of reported sadness, pessimistic  
196 thoughts and suicidal thoughts to avoid confounding symptoms related to PD as 'lassitude', 'inability  
197 to feel' or 'concentration difficulties;

198 2. the Starkstein scale (Starkstein et al. 1992) to identify apathy state and the severity of  
199 apathetic symptom;

200 3. the Barrat Impulsiveness Scale (BIS-11) (Fossati et al. 2001), a global self-report scale of  
201 impulsivity;

202 4. the 'Ardouin Scale of Behavior in Parkinson's Disease' (ASBPD) (Ardouin et al. 2009; Rieu  
203 et al. 2015). The ASBPD consist of 21 items, grouped into four parts: general psychological  
204 evaluation (part I), apathy (part II), non-motor fluctuations (part III) and hyperdopaminergic  
205 behavior (part IV). Part I successively evaluates depressive mood, hypomanic mood, anxiety,  
206 irritability and aggressiveness, hyperemotionality, and psychotic symptoms. Part II evaluates apathy  
207 in behavioral terms, that is, activity level, cognitive level, and emotional level. Part III evaluates the  
208 psychological state associated with the motor symptoms in the OFF and ON states in fluctuating  
209 patients. Part IV assesses the presence and the intensity of behavioral disorders induced by  
210 dopaminergic treatment, including nocturnal hyperactivity, diurnal somnolence, eating behavior,  
211 creativity, hobbyism, punding, risk-taking behavior, compulsive shopping, pathological gambling,  
212 hypersexuality, dopaminergic addiction, and excess in motivation. The timeframe of the assessment  
213 is the preceding month. Each item is rated on a five-point scale (severe disorder, 4; marked disorder,  
214 3; moderate disorder, 2; mild disorder, 1; absence of disorder, 0), by taking into account the severity  
215 and the frequency of the disorder and its impact. The interview is completed by a psychiatrist, a  
216 neuropsychologist, or a clinical psychologist familiar with PD and neuropsychiatric disorders in  
217 movement disorders. Total completion time is approximately 1 hour.

218

## 219 ***Neuropsychological assessment***

220 All PD patients underwent neuropsychological tasks to assess executive functioning and  
221 risk-taking behavior. The Conner's Performance Test (CPT-II) (Connors 2004), a 15 minutes  
222 computerized test, was used to evaluate attention and inhibition. The subject had to press the space  
223 bar of the computer as soon as he sees any letter on the screen, except the letter X, that he has to



224 hold back and press nothing. Variability in reaction time (expressed in millisecond) was used to  
225 assess attention capacity. Percentage of commission error (press when the letter is X) referred to  
226 inhibition abilities. The executive functioning was also assessed using : 1) conceptualization  
227 capacities measured by the reached number of criterion (range from 0 to 6) in the Modified  
228 Wisconsin Card Sorting Test (MCST) (Milner 1963); 2) shifting and reactive flexibility evaluated  
229 by the difference between the time scores of TMT-B and TMT-A in the Trail Making Test (TMT)  
230 (Reitan et al. 1985); 3) spontaneous flexibility and cognitive auto-activation skills using the  
231 phonological verbal fluency R with the total number of correct words given in 2 minutes (Cardebat  
232 et al. 1990).

233 To assess risk-taking behavior, we used a gambling task adapted from the Iowa Gambling  
234 Task (IGT) (Bechara et al. 1994). The subject saw on a screen 3 decks of cards labeled A, B, and C.  
235 Every time the subject picked a card, a message was displayed on the screen indicating the amount  
236 of money he immediately won or lost. At the same time, on the top of the screen, the total amount  
237 of money was displayed. The subject was asked to choose 50 cards and to win as much money as  
238 possible. Contrary to the IGT, subject was notified that some decks were more advantageous than  
239 others in order to avoid ambiguity and facilitate the comprehension of the rule. At the end of the  
240 task, subject was asked to appreciate if each deck was a winning, a losing or a neutral deck (called  
241 subjective variables). Subject can evaluate several decks as winning, losing or neutral. Decks had  
242 been constructed so that deck A was a neutral deck (equal opportunity for gains as losses). Deck B  
243 (small amount of money with a positive balance) was the winning deck with small gains but smaller  
244 losses. Deck C can be considered as the losing deck (high amount of money with a negative  
245 balance) as the subject won big gains but lost even more. Objective variables were the number of  
246 cards chosen in each deck. The score for each objective variable ranges from 0 to 50. The score for  
247 each subjective variable (valuation of the reward by appreciation of each deck) ranged from 0 to 2  
248 (0: loser deck; 1: neutral deck; 2: winner deck). This adaptation of the IGT was proposed to avoid  
249 ambiguity and to focus on the ability to resist to a big risky reward for the benefit of a smaller but  
250 safer reward rather than the capacity to detect and understand the rule. Especially, risk-taking  
251 behavior is evaluated by comparing the number of cards picked in each deck, subjects being aware  
252 of the advantageous/disadvantageous characteristic of the decks and constantly informed of his  
253 immediate reward and the total amount of money. Moreover, due to subjective variables, this task  
254 takes into account the valuation of the reward.

255

## 256 **Statistical Analysis**

257 For demographic characteristics and neuropsychological data a Mann-Whitney U-test or a  
258 Fisher exact test were used to compare CTRL-PD and ICD-PD groups. For risk-taking task,

259 comparison between the 3 groups (HV, CTRL-PD, ICD-PD) and between the three decks (A, B, and  
260 C) were performed by using a Kruskal Wallis test, followed when significant by a comparison of  
261 each group by a Mann-Whitney U-test. All results were considered significant if the p-value was  
262 less than 0.05 with no correction for multiple comparisons. Data were expressed as median +/-  
263 upper and lower quartiles. Statistical analysis was performed using Statistica 9.1 software (StatSoft  
264 France, F-94700, Maisons-Alfort).

265

## 266 **RESULTS**

### 267 **Patients' characteristics**

268 Thirty-seven patients (age range 33-69 years, men/women = 27/10) participated in this  
269 study. Seventeen patients were diagnosed as having one or more active ICD as the time of  
270 assessment. In ICD-PD group, specific criteria of the ASBPD confirmed presence of PG in 6  
271 patients, HS in 1 patient, CS in 2 patients, CE in 2 patients and 6 patients had multiple ICD (i.e.  
272 hypersexuality and pathological gambling or compulsive shopping and pathological gambling).  
273 Twenty patients without history of ICD were included in the CTRL-PD group (score  $\leq$  1 in all  
274 ICD's items of the ASBPD scale).

275 The two groups did not differ in gender, age, educational level, age at PD onset, PD  
276 duration, LEDD dopamine agonist dose, UPDRS-III while "on" state and MDRS score (see results  
277 in table 1). However, the 2 groups differed in total LEDD ( $p = 0,003$ ), possibly because CTRL-PD  
278 patients were recruited among those candidate for DBS and therefore needed more dopaminergic  
279 treatment to control the disease.

280 For neuropsychiatric characteristics, the two groups differed in MADRS dysphoria score ( $p$   
281 = 0,01), in Starkstein score ( $p = 0,01$ ) and in the BIS-11 score ( $p = 0,003$ ).

282

283 *[Insert Table 1]*

284

### 285 **Executive functions**

286 The two groups did not differ in attention capacities, conceptualization abilities, reactive  
287 flexibility, spontaneous flexibility and inhibition capacities.

288

289 *[Insert Table 2]*

290

### 291 **Risk-taking behavior results**

292 For the risk-taking task, the two groups of PD patients were compared to fifteen healthy  
293 volunteers (HV) matched in age, sex and educational level on the objective variables (number of

294 cards chosen in each deck) and the subjective variables (appreciation of each deck: winning, neutral  
295 or losing deck).

296 For each selection, all patients were able to clearly identify the feedback they received.

297 First, we analyzed the pattern of performances inside each group. For HV, there was no  
298 significant difference between decks for both objective and subjective variables (Kruskall-Wallis  
299 test,  $p = 0.61$  and  $p = 0.13$  respectively). On the contrary, ICD-PD patients and CTRL-PD patients  
300 both showed significant differences of the number of cards in each deck (Kruskall Wallis,  $p = 0.004$   
301 for CTRL-PD,  $p = 0.007$  for ICD-PD). For both groups, the number of cards chosen in the losing  
302 deck C (high amount of money) was higher as compared to the neutral deck A (Mann-Whitney test,  
303 ICD-PD,  $p=0,02$  ; CTRL-PD,  $p=0,003$ ) and to the winning deck B (small amount of money) (Mann-  
304 Whitney test, ICD-PD  $p=0,0001$  ; CTRL-PD  $p=0,003$ ). In addition, in the ICD-PD group, the  
305 number of card chosen in winning deck B was significantly lower than in neutral deck A (Mann-  
306 Whitney test,  $p = 0.04$ ). Subjective variables were not significantly different in the HV or the  
307 CTRL-PD groups (Kruskall-Wallis test,  $p = 0.13$  and  $p = 0.45$  respectively) whereas they were  
308 significantly different in the ICD-PD group (Kruskall-Wallis test,  $p = 0.01$ ). ICD-PD patients  
309 evaluated the wining deck B (small amount of money) loser as compared to neutral deck A (Mann-  
310 Whitney,  $p = 0.04$ ) and losing deck C (Mann-Whitney,  $p=0,01$ ).

311 Then, we compared the performances between the three different groups. When comparing  
312 PD patients to HV, we found no significant difference between HV and CTRL-PD groups for both  
313 objective and subjective variables. Furthermore, the ICD-PD group was significantly different from  
314 the HV for both variables: ICD-PD patients chose significantly less frequently the winning deck B  
315 (Mann Whitney,  $p=0,04$ ) and evaluated this deck more frequently as a losing one (Mann Whitney,  
316  $p=0,02$ ) as compared to HV. Moreover, ICD-PD patients evaluated the losing deck C more  
317 frequently as a winner than HV (Mann Whitney,  $p=0,02$ ). ICD-PD patients and CTRL-PD patients  
318 did not significantly differ for any deck for objective variables. Furthermore, for subjective  
319 variables, ICD-PD patients evaluated the winning deck B more frequently as a loser one than the  
320 CTRL-PD patients (Mann Whitney test,  $p=0,04$ ).

321

322 *[Insert Table 3]*

323

## 324 **DISCUSSION**

325 This study examined executive functioning and risk-taking in PD patients with ICD. As  
326 previously observed by Weintraub et al. (2010) and Voon et al. (2011a), we found that ICD-PD  
327 patients showed greater impulsivity, more depressive elements and lack of motivation than PD-  
328 CTRL patients.

329           Concerning the executive functioning, we found that ICD-PD patients performed similarly  
330 than CTL-PD patients, as supported by other studies, which showed no executive dysfunction  
331 including set shifting, inhibitory process and reactive flexibility in ICD patients compared to CTRL  
332 PD patients (Siri et al. 2010; Djamshidian et al. 2011a; Mack et al. 2013). This is against previous  
333 reports showing a positive association between ICD and cognitive dysfunction (Santangelo et al.  
334 2009; Vitale et al. 2011). Methodological and PD population's differences as well as small size of  
335 groups can highlight those discrepancies.

336           In this study, we addressed to the patients an experimental task to investigate risk-taking  
337 behavior and valuation of the reward. Our results showed that contrary to HV, both groups of PD  
338 patients behave similarly, choosing more frequently cards in the loser deck (high amount of money)  
339 compared to the other decks. These results confirm risk-taking behavior in PD with or without ICD  
340 (Delazer et al. 2009; Djamshidian et al. 2010; Rossi et al. 2010). Risk-taking behavior in PD  
341 probably involved dopamine replacement therapy's influence on mesolimbic spared circuit. For  
342 example, Steeves et al. (2009) in a PET neuroimaging study in PD patients with PG demonstrated  
343 decreased ventral striatal D2/D3 binding potential at baseline and a relatively greater decrease in  
344 binding potential in the ventral striatum during performance of a gambling task. Consistent with our  
345 results, Rao et al. (2010) found that both ICD-PD and CTL-PD groups behave similarly in a risk-  
346 taking task. Interestingly, in that functional magnetic resonance imaging, the authors showed that  
347 contrary to CTL-PD patients, ICD-PD patients demonstrated relatively diminished activity in the  
348 ventral striatum during risk-taking.

349           Our results suggested also that ICD-PD patients showed a specific deficit of the subjective  
350 estimation of the reward compared to patients without ICD, taking into account mainly the positive  
351 reinforced value of the decks, and less considering the value of the loss. These results are in line  
352 with studies exploring reinforcement sensitivity, demonstrating that via action on ventral striatal  
353 dopamine function, dopamine replacement therapy could potentially alter reward responsiveness  
354 and abilities to learn from negative decision outcomes (Franck et al. 2004; Pessiglione et al. 2006;  
355 Piray et al. 2014). For example, Franck et al. (2004) showed that PD patients without ICD have  
356 different learning and reward-seeking behaviors from healthy controls. PD patients showed exactly  
357 opposite learning patterns during their medication ON and OFF states: PD patients achieved more  
358 efficient learning by positive reinforcement during their ON medication state, whereas they  
359 performed better through negative feedback during their medication OFF state. In ICD-PD patients,  
360 it seems that dopamine agonist enhance the deviated learning pattern. Voon et al. (2010b) showed  
361 that dopamine agonist enhance the rate of a gain-specific learning and increase striatal prediction  
362 error activity observed in patient with ICD. Thus, ICD-PD patients can experiment a persistent  
363 "better than expected" outcome while taking dopamine agonist. Dopamine agonists also enhance

364 risk-taking behavior in ICD-PD patients (Voon et al. 2011b). While taking dopamine agonists, these  
365 patients seem to have a bias towards risky choice independent of the effect of loss aversion.  
366 Especially, Voon et al. (2011b) showed that neural activity in brain areas associated with risk  
367 representation, such as the ventral striatum, orbitofrontal cortex and anterior cingulate cortex, are  
368 decreased in these patients.

369 In our study, both PD groups presented risk-taking behavior during the task but only ICD-  
370 PD patients presented deficit in subjective appreciation of the reward. Especially, despite risk-taking  
371 behavior, when they were asked about their perception of deck's value at the end of the task, CTL-  
372 PD patients were able to correctly appreciate the reward. In contrary, ICD-PD patients presented a  
373 specific deficit of the subjective estimation of the value of stimuli. Recent studies focusing on  
374 influence of metacognitive skills on risk-taking process can probably contribute to understand this  
375 specific deficit presented by our ICD-PD patients. Metacognition is the ability to cognizant and  
376 have insight about the quality of the decision and to accurately judge whether the decision is surely  
377 a good one or not. Brevers et al. (2013) studied how metacognitive sensitivity may influence  
378 gamblers without PD's decision-making during the Iowa Gambling Task. Metacognition was  
379 assessed by asking participants to wager on their own decision. They found that gamblers tend to  
380 wager high while performing poorly on the Iowa Gambling Task and that the difference was not due  
381 to reward/loss sensitivity, current clinical or cognitive status. The same authors in a more recent  
382 study (Brevers et al. 2014) replicated these results with a non gambling task (grammatical  
383 paradigm). They found that compared to healthy volunteers, pathological gamblers without PD also  
384 erroneously think that they are performing much better than they actually are. Both studies  
385 suggested that pathological gamblers exhibit impaired metacognition in both gambling like and  
386 more 'neutral' situations of decision-making. In our study, the erroneous appreciation of deck's  
387 values specifically presented by ICD-PD patients could be linked to deficit in metacognitive skills.  
388 Indeed, in these patients, introspection's abilities are possibly based on the under-optimal behavior  
389 and lead to focus on the positive reinforcement value. In that perspective, Djamshidian et al.  
390 (2011b) showed that PD patients with ICD learn little of their mistakes, compared to ICD patients  
391 without PD. On the contrary, a recent study evaluating self-awareness in PD patients with ICD  
392 showed that presence of ICD was associated with awareness of impulsive behaviors, as indexed by  
393 greater cognitive insight into thoughts and behaviors on the BCIS (Mack et al. 2013). In the  
394 different studies cited above, different levels of awareness are probably involved and might explain  
395 the discrepancies of the results. All together, these results showed that ICD-PD patients are  
396 probably aware of ICD, but exhibit a fundamental impairment in their perception of winning or  
397 losing behaviors among various situation of decision-making and provide an interesting perspective  
398 to explain how metacognitive skills can contribute to the deficit of subjective estimation of the

399 reward presented by our ICD-PD patients.

400         There are however some limitations to our study. First, our sample size was small and may  
401 not have provided adequate power to detect smaller differences across variables. Second, this study  
402 focused on risk-taking behavior using an adapted task of the IGT to avoid fatigue, involvement of  
403 working memory and ambiguity in order to focus on the ability to resist a big risky reward for the  
404 benefit of a smaller but safer reward. This adaptation provides interesting results concerning risk-  
405 taking behavior in line with other studies (Rossi et al. 2010; Rao et al. 2010). Nevertheless, this  
406 experimental task is limited to the optimal selection in terms of rewarding or punishing outcomes  
407 under risky situations. The absence of ambiguity in our task reduces the interpretation in terms of  
408 decision-making process. Finally, a valuation of the reward was explored by an indirect measure  
409 (appreciation of each deck at the end of the risk-taking task) limiting the interpretation in terms of  
410 reward sensitivity. Despite these limitations, our study provides interesting findings on subjective  
411 perception of the reward, showing that subjective valuation of the reward is specifically impaired in  
412 PD patients with ICD compared to CTRL-PD patients.

413

414         In summary, our results show that executive pattern and risk-taking behavior are similar  
415 between ICD-PD patients and CTRL-PD patients, but patients with ICD present a specific deficit of  
416 the subjective estimation of the reward compared to CTRL-PD patients. Studies focusing on  
417 metacognitive skills provide an interesting perspective to explain our results. In that perspective,  
418 introspection's abilities of ICD-PD patients, possibly based on the under-optimal behavior, lead  
419 ICD-PD patients to focus on the positive reinforcement value. Others studies exploring subjective  
420 estimation of the reward and metacognitive skills are necessary to better understand their link and  
421 their influence on risk-taking behavior in PD patient with ICD.

422

423

424

425 **Ethical approval:** All procedures performed in studies involving human participants were in  
426 accordance with the ethical standards of the institutional and/or national research committee and  
427 with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

428 **REFERENCES**

429

430 Ardouin C, Chéreau I, Llorca PM, et al (2009) [Assessment of hyper- and hypodopaminergic  
431 behaviors in Parkinson's disease]. *Rev Neurol* 165:845-856. doi: 10.1016/j.neurol.2009.06.003

432 Bechara A, Damasio AR, Damasio H, Anderson SW (1994) Insensitivity to future  
433 consequences following damages to human prefrontal cortex. *Cognition* 50:7-15.

434 Brevers D, Cleeremans A, Bechara A, et al (2013) Impaired self-awareness in pathological  
435 gamblers. *J Gamb* 29:119-129. doi: 10.1007/s10899-012-9292-2

436 Brevers D, Cleermans A, Bechara A, et al (2014) Impaired metacognitive capacities in  
437 individual with problem gambling. *J Gamb Stud* 30:141-152. doi: 10.1007/s10899-012-9348-3.

438 Cardebat D, Doyon B, Puel M, Goulet P, Joannette Y. (1990) Formal and semantic lexical  
439 evocation in normal subjects. Performance and dynamics of production as a function of sex, age and  
440 educational level. *Acta Neurol Belg* 90:207-217.

441 Cilia R, Cho SS, Van Eimeren T, et al (2011) Pathological gambling in patients with  
442 Parkinson's disease is associated with fronto-striatal disconnection: a path modeling analysis. *Mov*  
443 *Disord* 26:225-233. doi: 10.1002/mds.23480.

444 Connors K. *Connors's Continuous Performance Test II (CPT-II V.5)*. 2004 Toronto: Multi-  
445 Heath Systems Inc.

446 Delazer M, Sinz H, Zamarian L, et al (2009) Decision-making under risk and under ambiguity  
447 in Parkinson's disease. *Neuropsychologia* 47:1901-1908. doi:  
448 10.1016/j.neuropsychologia.2009.02.034.

449 Djamshidian A, Jha A, O'Sullivan SS, et al (2010) Risk and learning in impulsive and  
450 nonimpulsive patients with Parkinson's disease. *Mov Disord* 25:2003-2010. doi:  
451 10.1002/mds.23247.

452 Djamshidian A, O'Sullivan SS, Lees A, Averbek BB (2011a) Stroop test performance in  
453 impulsive and non impulsive patients with Parkinson's disease. *Parkinsonism Relat Disord* 17:212-

454 214. doi: 10.1016/j.parkreldis.2010.12.014.

455 Djamshidian A, O'Sullivan SS, Wittmann BC, Lees AJ, Averbek BB (2011b) Novelty seeking  
456 behavior in Parkinson's disease. *Neuropsychologia* 49:2483-2488. doi:  
457 10.1016/j.neuropsychologia.2011.04.026.

458 Dubois B, Burn D, Goetz C et al (2007) Diagnostic procedures for Parkinson's disease  
459 dementia: recommendations from the movement disorder society task force. *Mov Disord.* 22:2314-  
460 2324.

461 Evans AH, Strafella AP, Weintraub D, Stacy M (2009) Impulsive and compulsive behaviors in  
462 PD. *Mov Disord* 24:1561-1570. doi: 10.1002/mds.22505.

463 Fossati A, Di Ceglie A, Acquarini E, Barratt ES (2001) Psychometric properties of an Italian  
464 version of the Barrat Impulsiveness Scale-11 (BIS-11) in nonclinical subjects. *J Clin Psychol*  
465 57:815-828.

466 Franck MJ, Seeberger LC, O'Reilly RC (2004) By carrot or by stick : cognitive reinforcement  
467 learning in parkinsonism. *Science* 306:1940-1943.

468 Gilleen J, Greenwood K, David A (2010) Lack of Insight and Awareness in Schizophrenia and  
469 Neuropsychiatric Disorders, in *Neuropsychiatric Disorders*, 1<sup>st</sup> Edition, Edited by Miyoshi K,  
470 Morimura Y, Maeda K. Springer Publishing. 33-49

471 Goerlich-Dobre KS, Probst C, Winter L, et al (2014) Alexithymia-An independent risk factor  
472 for impulsive-compulsive disorders in Parkinson's disease. *Mov Disord* 29:214-220. doi:  
473 10.1002/mds.25679

474 Gurevich EV, Joyce JN (1999) Distribution of dopamine D3 receptor expressing neurons in  
475 the human forebrain: comparison with D2 receptor expressing neurons. *Neuropsychopharmacology*  
476 20:60-80.

477 Housden CR, O'Sullivan SS, Joyce EM, Lees AJ, Roiser J (2010) Intact reward learning but  
478 elevated delay discounting in Parkinson's disease patients with impulsive-compulsive spectrum  
479 behaviors. *Neuropsychopharmacology* 235:2155-2164. doi: 10.1038/npp.2010.84.



480       Leroy I, Barraclough M, McKie S, Hinvest N, Evans J, Elliott R, McDonald K (2013)  
481 Dopaminergic influences on executive function and impulsive behavior in impulse control disorders  
482 in Parkinson's disease. *J Neuropsychol* 7:306-325. doi: 10.1111/jnp.12026.

483       Mack J, Okai D, Brown RG, et al (2013) The role of self-awareness and cognitive dysfunction  
484 in Parkinson's disease with and without impulse-control disorder. *J Neuropsychiatry Clin Neurosci*  
485 25:141-149. doi: 10.1176/appi.neuropsych.12030076.

486       Milner B (1963) Effects of different brain lesions on card sorting: the role of the frontal lobes.  
487 *Arch Neurol* 9:90-100.

488       Paulus MP (2005) Neurobiology of decision-making: quo vadis? *Brain Res Cogn Brain Res*  
489 23:2-10.

490       Pessiglione M, Seymour B, Flandin G, Dolan RJ, Frith CD (2006) Dopamine-dependent  
491 prediction errors underpin reward-seeking behavior in humans. *Nature* 442:1042-1045.

492       Piray P, Zeighami Y, Barhami F, Eissa AM, Hewedi DH, Moustafa AA (2014) Impulse control  
493 disorders in Parkinson's disease are associated with dysfunction in stimulus valuation but not action  
494 valuation. *J Neurosci* 34:7814-7824. doi: 10.1523/JNEUROSCI.4063-13.2014.

495       Poletti M, Bonuccelli U (2012) Impulse control disorders in Parkinson's disease: the role of  
496 personality and cognitive status. *J Neurol* 259:2269-2277. doi: 10.1007/s00415-012-6506-6.

497       Rao H, Mamikonyan E, Detre JA, Siderowf AD, Stern MB, Potenza MN, Weintraub D (2010)  
498 Decreased ventral striatal activity with impulse control disorders in Parkinson's disease. *Mov Disord*  
499 25:1660-1669. doi: 10.1002/mds.23147.

500       Reitan RM, Wolfson D. *The Trail making Test*. 1985 Tucson, A.Z: Neuropsychological Press.

501       Rieu I, Martinez-Martin P, Pereira B, et al (2015) International validation of a behavioral scale  
502 in Parkinson's disease without dementia. *Mov Disord* 30:705-713. doi: 10.1002/mds.26223.

503       Rossi M, Gershcovich ER, De Achaval D, et al (2010) Decision making in Parkinson's  
504 disease patients with and without PG. *Eur J Neurol* 17:97-102. doi: 10.1111/j.1468-  
505 1331.2009.02792.x.

506 Santangelo G, Vitale C, Trojano L, Verde F, Grossi D, Barone P (2009) Cognitive dysfunctions  
507 and pathological gambling in patients with Parkinson's disease. *Mov Disord* 24:899-905. doi:  
508 10.1002/mds.22472.

509 Siri C, Cilia R, De Gaspari D, et al (2010) Cognitive status of patients with Parkinson's  
510 disease and pathological gambling. *J Neurol* 257:247-252. doi: 10.1007/s00415-009-5301-5.

511 Starkstein SE, Mayberg HS, Leiguarda R, Preziosi TJ, Robinson R (1992). A prospective  
512 longitudinal study of depression, cognitive decline, and physical impairments in patients with  
513 Parkinson's disease. *J Neurol Neurosurg Psychiatry* 55:377-382.

514 Steeves TD, Miyasaki J, Zurowski M, et al (2009) Increased striatal dopamine release in  
515 Parkinsonian patients with pathological gambling: a [<sup>11</sup>C] raclopride PET study. *Brain* 132:1376-  
516 1385. doi:10.1093/brain/awp054.

517 Suzuki A, Aoshima T, Fukasawa T, et al (2005) A three-factor of the MADRS in major  
518 depressive disorder. *Depress Anxiety* 21:95-97.

519 Vitale C, Santangelo G, Trojano L, et al (2011) Comparative neuropsychological profile of  
520 pathological gambling, hypersexuality and compulsive eating in Parkinson's disease. *Mov Disord*  
521 26:830-836. doi: 10.1002/mds.23567.

522 Voon V, Reynolds B, Brezing C, et al (2010a) Impulse choice and response in dopamine  
523 agonist-related impulse control behaviors. *Psychopharmacology* 207:645-659. doi: 10.1007/s00213-  
524 009-1697-y.

525 Voon V, Pessiglione M, Brezing C, et al (2010b) Mechanisms underlying dopamine-mediated  
526 reward bias in compulsive behaviors. *Neuron* 65:135-142 doi: 10.1016/j.neuron.2009.12.027.

527 Voon V, Sohr M, Lang AE, et al (2011a) Impulse control disorders in Parkinson's disease: a  
528 multicenter case-control study. *Ann Neurol* 69:986-996. doi: 10.1002/ana.22356.

529 Voon V, Gao J, Brezing C et al (2011b) Dopamine agonists and risk: impulse control disorders  
530 in Parkinson's disease. *Brain* 134:1438-1446. doi: 10.1093/brain/awr080.

531 Vriend C, Nordbeck AH, Booij J, et al (2014) Reduced dopamine transporter binding predate

532 impulse control disorders in Parkinson's disease. *Mov Disord* 29:904-911. doi: 10.1002/mds.25886.

533 Weintraub D, Koester J, Potenza MN, et al (2010) Impulse control disorders in Parkinson's

534 disease: a cross-sectional study of 3090 patients. *Arch Neurol* 67:589-595. doi:

535 10.1001/archneurol.2010.65.

## TABLES

*Table 1: Demographic and clinical aspects of PD patients with and without ICD*

*Values are median (lower-upper quartile). P-value: Mann-Whitney test between groups.*

Characteristics	ICD-PD n = 17	CTL-PD n = 20	p
Men/Women, No	14/3	13/7	0,24
Age (Yr)	55 (37-69)	55 (40-62)	0,52
Education (Yr)	7 (3-7)	7 (3-7)	0,45
Age at PD onset (Yr)	48 (32-65)	48 (35-55)	0,57
PD duration (Yr)	7 (2-10)	5,5 (4-12)	0,60
LEDD (mg/dose)	897,5 (299,88-1247,33)	1049,89 (527,05-1549,84)	0,003
LEDD dopamine agonist (mg/dose)	299,94 (77-718)	340,23 (66,68-700)	0,78
UPDRS-III score while on state	7 (0-23)	8,5 (0-34)	0,62
Dysphoria specific MADRS score	6 (0-13)	1,5 (0-7)	0,01
Starkstein scale score	7 (3-14)	4 (0-10)	0,01
MDRS score	140 (133-144)	139 (131-143)	0,07

*Table 2: Neuropsychological compares between patients with PD with and without ICD.*

*Values are median (lower-upper quartile). P-value: Mann-Whitney test between groups.*

	ICD-PD n = 17	CTL-PD n = 20	p
<b>Impulsivity</b>			
Global BIS-11	63 (48-81)	52 (36-70)	0,003
<b>Attention</b>			
RT variability CPT	88,5 (4,74-202,2)	82,9 (3,05-193,4)	0,68
<b>Executive functioning</b>			
criterion number MSCT	6 (5-6)	6 (3-6)	0,23
TMT B-A	34 (6-149)	45,2 (10-78)	0,56
fluency R	26 (6-43)	20 (8-38)	0,08
% commission CPT	22,2 (4,7-38,9)	20,8 (5,6-70,8)	0,67

*Table3: Compares between the two PD groups and the healthy volunteers on the risk-taking task*

*Values are median (lower-upper quartile). P-value: Kruskal-Wallis test for each deck between groups.*

*<sup>a</sup>Significantly different from HV ; <sup>b</sup>Significantly different from CTL-PD ; <sup>c</sup>Significantly different from deck B ;*

*<sup>d</sup>Significantly different from deck C, Mann Whitney test.*

	ICD-PD n = 17	CTL-PD n = 20	HV n = 15	p
<i>Objective variables</i>				
Number of cards neutral deck A	17 (7-14) <sup>d</sup>	15 (8-23) <sup>d</sup>	15 (6-24)	0,58
Number of cards winning deck B	14 (5-18) <sup>a, d</sup>	15 (5-26) <sup>d</sup>	17 (10-33)	0,01
Number of cards losing deck C	19 (12-33)	20 (12-34)	16 (10-30)	0,21
<i>Subjective variables</i>				
Appreciation neutral deck A	2 (0-2) <sup>c</sup>	1 (0-2)	1 (0-2)	0,24
Appreciation winning deck B	0 (0-2) <sup>a, b, d</sup>	1,5 (0-2)	2 (0-2)	0,04
Appreciation losing deck C	2 (0-2) <sup>a</sup>	1,5 (0-2)	0 (0-2)	0,06